Company: PSTV
Filing Date: 2025-08-04
Form Type: DRS
Source: 0000950123-25-006916
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-04
Form: DRS
Chunk 4
---
5

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                                               |     | ii |
| PROSPECTUS SUMMARY                                                                  |     |  1 |
| THE OFFERING                                                                        |     |  2 |
| RISK FACTORS                                                                        |     |  4 |
| FORWARD-LOOKING STATEMENTS                                                          |     |  7 |
| THE LINCOLN PARK TRANSACTION                                                        |     |  8 |
| USE OF PROCEEDS                                                                     |     | 14 |
| DILUTION                                                                            |     | 16 |
| THE SELLING STOCKHOLDER                                                             |     | 17 |
| MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER                            
 MATTERS                                                                             |     | 19 |
| DESCRIPTION OF CAPITAL STOCK                                                        |     | 20 |
| PLAN OF DISTRIBUTION                                                                |     | 25 |
| LEGAL MATTERS                                                                       |     | 27 |
| EXPERTS                                                                             |     | 27 |
| WHERE YOU CAN FIND MORE INFORMATION                                                 |     | 27 |
| INCORPORATION BY REFERENCE                                                          |     | 28 |
| DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES |     | 29 |

i

Confidential Treatment Requested by Plus Therapeutics, Inc.

Pursuant to 17 C.F.R. Section 200.83

ABOUT THIS PROSPECTUS

This prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), and
that includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings
“Where You Can Find More Information” and “Incorporation by Reference” before making your investment decision.

You
should rely only on the information provided in this prospectus or in a prospectus supplement or any free writing prospectuses or amendments thereto. Neither we, nor the selling stockholder, have authorized anyone else to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus is accurate only as of the date hereof. Our business, financial condition, results
of operations and prospects may have changed since that date.